# Iteration 3 History

## User

SYSTEM: Welcome to **Iteration 3 of 3** of our *in silico* drug discovery project:

Here is the context of the project objective and scope of this iteration:

----------------------------------------------------------------------


You are now in the 'Final Lead Optimization' phase for designing an AKT1 inhibitor. You need to show your final results and make a decision.

==============================================================
FINAL LEAD OPTIMIZATION CONTEXT
--------------------------------------------------------------
1. The previous lead optimization phase ended as summarized above. We have:

   - 5 active and 5 inactive compounds (all with docking + PLIP).
   - A set of de novo molecules from the AI Expert, each with
     docking + PLIP data.
   - A target docking improvement of at least 10% over
     the best known active compound.

2. Participants:
   - Medicinal Chemist: Make modifications to the de novo molecules to increase the activity, and drug-like properties. Evaluates the new molecules with its tools. And finalizes the 10 molecules.
   - Ranking agent: Rank the molecules based on the docking scores and the other metrics.

3. Automatic Workflow:
   - Each time the Medicinal Chemist proposes a set of analogs,
     docking is run automatically, then PLIP highlights
     protein-ligand interactions.
   - The Ranking Agent see these results
     and rank them

==============================================================
RULES & FLOW
--------------------------------------------------------------
- Docking + PLIP run automatically for each analog.
- We track progress iteration by iteration, aiming to see
  if the docking surpasses the 10% improvement threshold.
- Ranking Agent should select 10 best molecules.
- Finally lets have 10 optimized molecules.
- Most important thing is for all molecules to have docking scores and other metrics.
This way ranking agent can rank them and we can see the progress.
  
==============================================================
END OF SYSTEM PROMPT


----------------------------------------------------------------------

This iteration builds upon the overall project goals and the specific directives established by the Principal Researcher at the end of the previous iteration.

**Guiding Context from Previous Iteration (Principal Researcher's Summary & Directives for this Current Iteration):
**----------------------------------------------------------------------
# Comprehensive Iteration Summary and Directives for Next Iteration LEAD OPTIMIZATION

## 1. Executive Summary of Iteration 2

In this second iteration, our team successfully advanced the optimization of AKT1 inhibitors by focusing on three main scaffolds identified in Iteration 1: benzoquinazoline, piperidine-containing, and pyridine-pyrazole scaffolds. The primary objectives were to balance binding affinity with drug-like properties, reduce lipophilicity of the benzoquinazoline scaffold, enhance hydrogen bonding networks in the piperidine-containing scaffold, and improve binding affinity of the pyridine-pyrazole scaffold while maintaining excellent drug-likeness. The Medicinal Chemist generated 9 new optimized compounds, which were then evaluated by the Ranking Agent and critically assessed by the Scientific Critic. Significant progress was made in reducing lipophilicity while maintaining strong binding affinity, with several compounds achieving an excellent balance of potency and drug-like properties. The pyridine-pyrazole scaffold emerged as particularly promising, with MC:I2:N5:G2 ranked as the top candidate due to its exceptional balance of binding affinity (-10.59 kcal/mol) and drug-likeness (QED 0.63).

<ranking>
{"MC:I2:N5:G2": 1, "MC:I1:N4:G1": 2, "MC:I2:N7:G2": 3, "MC:I2:N3:G3": 4, "MC:I1:N1:G1": 5, "MC:I2:N2:G2": 6, "AI:I1:N1:G0": 7, "MC:I2:N8:G3": 8, "MC:I2:N6:G3": 9, "MC:I2:N9:G2": 10, "MC:I2:N1:G2": 11, "DA:I1:N5:G0": 12, "MC:I2:N4:G2": 13, "MC:I1:N3:G1": 14, "MC:I1:N2:G1": 15}
</ranking>

## 2. Key *In Silico* Findings & Discoveries from Iteration 2

### Scaffold-Specific Optimizations and Achievements

1. **Pyridine-Pyrazole Scaffold Optimization:**
   - **MC:I2:N5:G2** (docking: -10.59 kcal/mol, QED: 0.63, logP: 2.41) emerged as the top-ranked compound, demonstrating an exceptional balance of binding affinity and drug-likeness. This compound replaced the carbamate in MC:I1:N4:G1 with a fluoroacetamide group, improving metabolic stability while maintaining critical interactions with TRP80, ASN204, SER205, HIS207, THR211, and ASP292.
   - **MC:I2:N6:G3** (docking: -9.04 kcal/mol, QED: 0.48, logP: 2.94) further explored this scaffold by replacing the fluoroacetamide with a fluoromethylurea to enhance hydrogen bonding capabilities.
   - This series consistently demonstrated excellent drug-likeness (QED 0.48-0.65) and optimal lipophilicity (logP 2.41-3.01), making it highly promising for further development.

2. **Benzoquinazoline Scaffold Optimization:**
   - Significant progress in reducing lipophilicity from the original DA:I1:N5:G0 (logP 6.86) to as low as 4.64 in MC:I2:N3:G3, while maintaining strong binding affinity.
   - **MC:I2:N3:G3** (docking: -10.97 kcal/mol, QED: 0.21, logP: 4.64) incorporated a hydroxyl-dimethylaminoethyl side chain to significantly improve solubility while maintaining good binding.
   - **MC:I2:N2:G2** (docking: -12.50 kcal/mol, QED: 0.25, logP: 5.32) achieved a good balance of binding affinity and reduced lipophilicity through the introduction of a dimethylaminoethyl side chain.
   - **MC:I2:N1:G2** (docking: -14.86 kcal/mol, QED: 0.14, logP: 6.07) demonstrated exceptional binding affinity through a hybrid design incorporating pyrazole and aminopyridine elements, though drug-likeness remained suboptimal.

3. **Piperidine-Containing Scaffold Optimization:**
   - **MC:I2:N7:G2** (docking: -10.89 kcal/mol, QED: 0.40, logP: 2.81) successfully enhanced the hydrogen bonding network through the addition of a hydroxyl group to the tetrahydronaphthalene moiety and replacement of one chlorine with fluorine.
   - **MC:I2:N8:G3** (docking: -9.71 kcal/mol, QED: 0.39, logP: 2.75) further optimized this scaffold by adding a fluorine to the tetrahydronaphthalene moiety to enhance metabolic stability.
   - This series consistently achieved favorable lipophilicity (logP 2.75-3.62) while maintaining good binding affinity.

### Structure-Activity Relationship (SAR) Insights

1. **Key Binding Interactions:**
   - Pi-stacking with TRP80 remains essential for high-affinity binding across all scaffolds.
   - Multiple hydrogen bonds with SER205, THR211, and ASP292 consistently enhance binding affinity.
   - The introduction of fluorine substituents generally maintains or improves binding while enhancing metabolic stability.

2. **Lipophilicity vs. Binding Affinity Trade-offs:**
   - Reducing lipophilicity in the benzoquinazoline scaffold typically results in some reduction in binding affinity, but strategic modifications can minimize this trade-off.
   - The pyridine-pyrazole scaffold offers the best balance of binding affinity and drug-likeness, with minimal trade-offs between these properties.
   - Optimal logP values (2-4) can be achieved while maintaining binding scores better than -10 kcal/mol.

3. **Functional Group Effects:**
   - Replacement of carbamates with fluoroacetamide or fluoromethylurea groups improves metabolic stability while maintaining hydrogen bonding capabilities.
   - Introduction of hydroxyl groups to aromatic rings enhances hydrogen bonding and reduces lipophilicity.
   - Basic nitrogen-containing groups (e.g., dimethylaminoethyl) improve solubility but may introduce metabolic liabilities.

4. **Hybrid Design Success:**
   - Combining elements from different scaffolds (e.g., MC:I2:N1:G2, MC:I2:N4:G2) can achieve exceptional binding affinity but often at the expense of drug-likeness.
   - Strategic incorporation of heterocycles (pyrazole, pyridine) can reduce lipophilicity while maintaining key binding interactions.

## 3. *In Silico* Challenges & Unresolved Questions from Iteration 2

### Methodological Limitations

1. **Docking Score Reliability:**
   - Exceptionally high binding affinities reported for some compounds (e.g., -14.86 kcal/mol for MC:I2:N1:G2) exceed typical ranges for protein-ligand interactions, suggesting potential overestimation.
   - Lack of consensus scoring using multiple docking algorithms limits confidence in absolute binding affinity values.
   - Absence of molecular dynamics simulations to validate the stability of predicted binding poses.

2. **Physicochemical Property Limitations:**
   - Incomplete assessment of important parameters such as topological polar surface area (TPSA), which is critical for oral absorption and blood-brain barrier penetration.
   - Several top-ranked compounds have molecular weights exceeding 500 Da, potentially compromising oral bioavailability.
   - Limited consideration of ionization states at physiological pH, which can significantly affect absorption and distribution.

3. **Binding Mode Uncertainty:**
   - Reliance on static docking poses without assessment of binding stability over time.
   - Uncertainty about the flexibility of the binding site and its impact on ligand binding.

### Scientific Gaps

1. **Selectivity Assessment:**
   - No evaluation of selectivity for AKT1 over related kinases (AKT2, AKT3).
   - Limited exploitation of AKT1-specific binding site features to enhance selectivity.
   - Absence of comparative docking against related kinases to predict selectivity profiles.

2. **Metabolic Stability Concerns:**
   - Insufficient systematic assessment of metabolic stability for optimized compounds.
   - Several compounds contain structural features that may be susceptible to rapid metabolism:
     - Fluoroacetamide in MC:I2:N5:G2 may pose toxicity concerns due to potential conversion to fluoroacetate.
     - Tertiary amine in MC:I2:N3:G3 may be susceptible to oxidative metabolism.
     - Mixed halogen substitution in MC:I2:N7:G2 may create metabolic liabilities.

3. **Pharmacophore Development:**
   - Lack of a formal pharmacophore model based on the optimized compounds.
   - Need for more systematic identification of essential structural features for AKT1 inhibition.

4. **Synthetic Feasibility:**
   - Limited consideration of synthetic routes for complex molecules.
   - Some highly ranked compounds (e.g., MC:I2:N1:G2) have complex structures that may present synthetic challenges despite reasonable SA scores.

## 4. Strategic Outlook & Actionable *In Silico* Directives for Next Iteration

### a. Overarching Goal for Iteration 3

The primary objective for Iteration 3 is to finalize the selection and optimization of 10 candidate molecules for AKT1 inhibition, focusing on addressing the identified limitations and scientific gaps from Iteration 2. Specifically, we aim to:

1. Refine the top-ranked compounds from Iteration 2 to address potential metabolic liabilities and toxicity concerns while maintaining binding affinity.
2. Enhance selectivity for AKT1 by targeting AKT1-specific binding site features.
3. Improve physicochemical properties to ensure optimal drug-likeness, with particular attention to molecular weight and topological polar surface area.
4. Develop a comprehensive understanding of structure-activity relationships across the three main scaffolds.
5. Ensure all final candidates have balanced profiles of binding affinity, drug-likeness, and predicted ADMET properties.

### b. Specific Tasks & Focus Areas for Each Available Agent in Iteration 3

#### For Principal Researcher (Myself):

1. **Strategic Coordination:**
   - Oversee the final optimization and selection of 10 candidate molecules across the three main scaffolds.
   - Ensure balanced consideration of binding affinity, drug-likeness, and predicted ADMET properties.
   - Develop a comprehensive pharmacophore model based on the final set of optimized compounds.

2. **Selectivity Enhancement:**
   - Identify AKT1-specific binding site residues that differ from AKT2/AKT3.
   - Guide the Medicinal Chemist in targeting these residues to enhance selectivity.

3. **Final Analysis and Documentation:**
   - Synthesize findings from the Medicinal Chemist and Ranking Agent to select the final 10 candidates.
   - Prepare comprehensive documentation of the entire optimization process, including structure-activity relationships and binding mode analyses.
   - Develop recommendations for future experimental validation of the selected candidates.

#### For Medicinal Chemist:

1. **Pyridine-Pyrazole Scaffold Refinement:**
   - Focus on MC:I2:N5:G2 (SMILES: `CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)CF`) and MC:I1:N4:G1.
   - Replace the potentially toxic fluoroacetamide in MC:I2:N5:G2 with safer bioisosteres that maintain hydrogen bonding capabilities (e.g., oxadiazole, isoxazole).
   - Explore modifications to enhance interactions with AKT1-specific residues.
   - Optimize the piperidine substituent to improve binding while maintaining excellent drug-likeness.

2. **Benzoquinazoline Scaffold Optimization:**
   - Focus on MC:I2:N3:G3 (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3cnn(CC(O)N(C)C)c3)cc2)CC1`) and MC:I2:N2:G2.
   - Address potential metabolic liabilities in the hydroxyl-dimethylaminoethyl side chain by exploring less basic alternatives that maintain solubility enhancement.
   - Further reduce lipophilicity by introducing additional polar groups or replacing aromatic rings with heterocycles.
   - Aim for compounds with logP < 5 and molecular weight < 550 Da while maintaining binding scores better than -10 kcal/mol.

3. **Piperidine-Containing Scaffold Enhancement:**
   - Focus on MC:I2:N7:G2 (SMILES: `CC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5Cl`) and MC:I1:N1:G1.
   - Address the mixed halogen substitution pattern by exploring more consistent halogenation strategies.
   - Simplify the structure to reduce the number of chiral centers or specify the preferred stereochemistry based on docking results.
   - Enhance metabolic stability by identifying and modifying potential metabolic soft spots.

4. **General Directives:**
   - Use the VINA_REPORT tool to evaluate all modifications.
   - For each modification, assess the impact on docking score, drug-likeness (QED), synthetic accessibility (SA score), and predicted interactions.
   - Calculate and consider topological polar surface area (TPSA) for improved predictions of oral absorption.
   - Aim for compounds with balanced profiles: docking scores better than -10 kcal/mol, QED > 0.5, logP between 2-5, and molecular weight < 500 Da.
   - Generate at least 12 optimized compounds to allow for selection of the final 10 candidates.

#### For Ranking Agent:

1. **Enhanced Ranking Criteria:**
   - Develop a more comprehensive composite score that incorporates:
     - Docking score (weighted at 35%)
     - Drug-likeness (QED) (weighted at 25%)
     - Optimal lipophilicity (logP between 2-5) (weighted at 15%)
     - Molecular weight (penalty for MW > 500 Da) (weighted at 10%)
     - Synthetic accessibility (SA score) (weighted at 10%)
     - Topological polar surface area (optimal range 75-140 Å²) (weighted at 5%)

2. **Selectivity Prediction:**
   - Evaluate compounds based on their interactions with AKT1-specific residues.
   - Assign higher rankings to compounds that form interactions with residues unique to AKT1 compared to AKT2/AKT3.

3. **Metabolic Stability Consideration:**
   - Identify and penalize compounds with structural features associated with metabolic instability.
   - Assign higher rankings to compounds with structures designed to address metabolic liabilities.

4. **Ranking Directives:**
   - Rank all compounds generated across all three iterations.
   - Provide detailed rationales for rankings, highlighting key strengths and weaknesses.
   - Identify the top 10 compounds as final candidates, ensuring representation from each of the three main scaffolds.
   - Provide sub-rankings for each of the three main scaffolds.

### c. Key Performance Indicators (KPIs) for Iteration 3

1. **Binding Affinity Metrics:**
   - All final candidates should have docking scores better than -10 kcal/mol.
   - At least 5 compounds should form hydrogen bonds with AKT1-specific residues.
   - All compounds should maintain pi-stacking interactions with TRP80.

2. **Drug-Likeness Metrics:**
   - At least 7 of the final 10 compounds should have QED > 0.5.
   - All final candidates should have logP between 2-5.
   - All final candidates should have molecular weight < 550 Da (preferably < 500 Da).
   - Topological polar surface area should be in the range of 75-140 Å² for optimal oral absorption.

3. **Structural Diversity:**
   - The final 10 candidates should include representatives from each of the three main scaffolds.
   - At least 3 compounds should be from the pyridine-pyrazole scaffold series.
   - At least 2 compounds should be from the benzoquinazoline scaffold series.
   - At least 2 compounds should be from the piperidine-containing scaffold series.

4. **Metabolic Stability:**
   - All final candidates should address the metabolic liabilities identified in Iteration 2.
   - No compounds should contain potentially toxic groups (e.g., fluoroacetamide).
   - Compounds should minimize the number of metabolic soft spots.

5. **Comprehensive Analysis:**
   - Development of a formal pharmacophore model for AKT1 inhibition.
   - Clear structure-activity relationships for each scaffold series.
   - Identification of essential structural features for AKT1 selectivity.

By focusing on these directives and KPIs, Iteration 3 will culminate in the selection of 10 optimized AKT1 inhibitor candidates with balanced profiles of binding affinity, drug-likeness, and predicted ADMET properties, representing the successful completion of our *in silico* drug discovery project.
----------------------------------------------------------------------

**Molecule Context:** This refers to all molecules that were generated, modified, or analyzed in the previous iteration. Key highlights include: {
   "molecules": [
      {
         "originalData": {
            "activity": "active",
            "computedProperties": {
               "dockingScore": -6.49,
               "logP": 3.72,
               "molecularWeight": 580.44,
               "qed": 0.29,
               "sas": 3.51
            },
            "friendlyId": "DA:I1:N1:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Potent AKT1 inhibitor with pChEMBL value of 8.3. Shows H-bonds with SER205, LEU78, GLN79, TRP80; Hydrophobic interactions with VAL270, TRP80.",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "active",
            "computedProperties": {
               "dockingScore": -6.81,
               "logP": 4.4,
               "molecularWeight": 526.01,
               "qed": 0.4,
               "sas": 3.59
            },
            "friendlyId": "DA:I1:N2:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Active AKT1 inhibitor with pChEMBL value of 6.8. Shows H-bonds with SER205, ASN54, GLN79, TRP80; Hydrophobic interactions with LEU264, LYS268, VAL270, ASP292, TRP80; Pi-stacking with TRP80.",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(/C=C/[C@@H]3CCCNC[C@H]3NC(=O)c3ccncc3)cc2)c1F.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "active",
            "computedProperties": {
               "dockingScore": -6.34,
               "logP": 4.08,
               "molecularWeight": 566.46,
               "qed": 0.35,
               "sas": 3.5
            },
            "friendlyId": "DA:I1:N3:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Active AKT1 inhibitor with pChEMBL value of 6.45. Shows H-bonds with THR211, ASP274, LYS276, LEU295, CYS296; Hydrophobic interactions with TRP80; Pi-stacking with TYR272; Pi-cation with LYS276.",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(CO[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "active",
            "computedProperties": {
               "dockingScore": -7.58,
               "logP": 3.29,
               "molecularWeight": 579.46,
               "qed": 0.32,
               "sas": 3.47
            },
            "friendlyId": "DA:I1:N4:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Highly potent AKT1 inhibitor with pChEMBL value of 8.4. Shows H-bonds with GLN203, THR211, LYS268; Hydrophobic interactions with LEU210, LYS268, TYR272, ASP292, TRP80; Pi-stacking with TRP80; Halogen bond with LYS268.",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(C(=O)N[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "active",
            "computedProperties": {
               "dockingScore": -13.56,
               "logP": 6.86,
               "molecularWeight": 511.63,
               "qed": 0.27,
               "sas": 2.48
            },
            "friendlyId": "DA:I1:N5:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Active AKT1 inhibitor with pChEMBL value of 6.54 and excellent docking score. Shows H-bonds with SER205, THR211, GLN79; Hydrophobic interactions with LEU210, LEU264, LYS268, VAL270, TYR272, ASN53, GLN79, TRP80, THR82, ILE84; Pi-stacking with TRP80; Salt bridge with ASP292.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccccc3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "activity": "inactive",
            "computedProperties": {
               "dockingScore": -12.85,
               "logP": 4.68,
               "molecularWeight": 494.6,
               "qed": 0.21,
               "sas": 3.13
            },
            "friendlyId": "DA:I1:N6:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive AKT1 inhibitor with pChEMBL value of 5.26 despite good docking score. Shows H-bonds with GLN203, SER205, ASP292, GLN79, THR82; Hydrophobic interactions with VAL270, ASP292, ASN53, TRP80; Pi-stacking with TRP80.",
            "structure": {
               "smiles": "Cn1ccc2ccc3c4[nH]c5c(CCCN[C@H]6CC[C@H](O)CC6)cccc5c4c4c(c3c21)C(=O)NC4=O"
            }
         }
      },
      {
         "originalData": {
            "activity": "inactive",
            "computedProperties": {
               "dockingScore": -6.97,
               "logP": 3.8,
               "molecularWeight": 529.01,
               "qed": 0.33,
               "sas": 3.46
            },
            "friendlyId": "DA:I1:N7:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive AKT1 inhibitor with pChEMBL value of 4.6. Shows H-bonds with THR211, TRP80; Hydrophobic interactions with VAL270, TYR272, ASP292, GLN79, TRP80; Pi-stacking with TRP80.",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(NC[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "inactive",
            "computedProperties": {
               "dockingScore": -6.96,
               "logP": 3.23,
               "molecularWeight": 529.01,
               "qed": 0.33,
               "sas": 3.43
            },
            "friendlyId": "DA:I1:N8:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive AKT1 inhibitor with pChEMBL value of 5.52. Shows H-bonds with GLN203, SER205, GLN59, TRP80; Hydrophobic interactions with LEU202, LEU210, LEU264, LYS268, VAL270, GLN79, TRP80; Pi-stacking with TRP80.",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(CN[C@@H]3CCCNC[C@H]3NC(=O)c3ccncc3)cc2)c1F.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "inactive",
            "computedProperties": {
               "dockingScore": -11.96,
               "logP": 7.46,
               "molecularWeight": 510.64,
               "qed": 0.26,
               "sas": 2.47
            },
            "friendlyId": "DA:I1:N9:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive AKT1 inhibitor with pChEMBL value of 5.5 despite good docking score. Shows H-bonds with TRP80; Hydrophobic interactions with LEU210, LEU264, VAL270, TYR272, ILE290, ASN53, GLN79, TRP80.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3cc4ccccc4nc3-c3ccccc3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "activity": "inactive",
            "computedProperties": {
               "dockingScore": -12.63,
               "logP": 6.1,
               "molecularWeight": 459.58,
               "qed": 0.32,
               "sas": 2.47
            },
            "friendlyId": "DA:I1:N10:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive AKT1 inhibitor with pChEMBL value of 5.89 despite good docking score. Shows H-bonds with SER205, ASP274, ASN279, PHE293, THR82; Hydrophobic interactions with LEU210, LEU264, TYR272, ASP292, TRP80; Pi-stacking with TRP80.",
            "structure": {
               "smiles": "N#Cc1cnc(-c2ccc(CNCc3ccc(-c4csnn4)cc3)cc2)c(-c2ccccc2)c1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -11.2,
               "logP": 3.82,
               "qed": 0.58,
               "sas": 3.69
            },
            "friendlyId": "AI:I1:N1:G0",
            "rationale": "This compound exhibits excellent binding affinity (-11.20 kcal/mol) with key interactions at GLN203 and TRP80. The molecule contains a bicyclic core with a piperidine ring system that positions functional groups for optimal interactions with the binding site. The dichlorophenyl group likely enhances binding through halogen interactions.",
            "structure": {
               "smiles": "CC(=O)NCC(N1C(=O)CN2CCC(C3=CC=CC4=C3CCC4)CC2)C(=O)NC1C5=C(Cl)C=CC=C5Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.37,
               "logP": 3.88,
               "qed": 0.46,
               "sas": 3.85
            },
            "friendlyId": "AI:I1:N2:G0",
            "rationale": "This molecule forms a strong pi-stacking interaction with the critical TRP80 residue and hydrogen bonding with ASN53. The nitro group serves as a hydrogen bond acceptor, while the fused ring system provides rigidity for optimal binding pose. The styrene-like moiety extends into a hydrophobic pocket.",
            "structure": {
               "smiles": "C12NC(C3=CC=CC([N+1](=O)[O-1])=C3C)C=CC1=C2NC(=O)/C=C/C4=CC=CC=C4C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.05,
               "logP": 4.54,
               "qed": 0.57,
               "sas": 3.87
            },
            "friendlyId": "AI:I1:N3:G0",
            "rationale": "This compound forms multiple hydrogen bonds with key residues (THR211, ILE290, ASP292, GLN79) and pi-stacking with TRP80. The pyrazole ring provides hydrogen bond donors/acceptors, while the chlorophenyl group occupies a hydrophobic pocket. The piperazine moiety likely interacts with acidic residues in the binding site.",
            "structure": {
               "smiles": "O=C(NC1=C[NH1]N=C1C=NC=C(C2=CC=CC(Cl)=C2)CCCC)N3CCNCC3C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.96,
               "logP": 3.66,
               "qed": 0.49,
               "sas": 3.03
            },
            "friendlyId": "AI:I1:N4:G0",
            "rationale": "This tetrahydro-beta-carboline derivative forms key interactions with TRP80 through both hydrogen bonding and pi-stacking. The nitrophenyl group serves as an electron-withdrawing substituent that enhances binding through polar interactions. The hydroxypropyl chain provides additional hydrogen bonding opportunities.",
            "structure": {
               "smiles": "OCCCC1NCC2=C1[NH1]C3=CC=C(C4=CC=C([N+1](=O)[O-1])C=C4)C=C23"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.83,
               "logP": 2.91,
               "qed": 0.72,
               "sas": 3.44
            },
            "friendlyId": "AI:I1:N5:G0",
            "rationale": "This compound has excellent drug-likeness (QED 0.72) and forms multiple hydrogen bonds with ASN204, SER205, and HIS207. The pyridine and pyrazole rings provide a rigid scaffold with multiple hydrogen bond acceptors. The chloropiperidine group occupies a hydrophobic pocket, while the hydroxyethyl chain offers additional hydrogen bonding capability.",
            "structure": {
               "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(Cl)C3)=C1CCO"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.57,
               "logP": 4.59,
               "qed": 0.51,
               "sas": 2.61
            },
            "friendlyId": "AI:I1:N6:G0",
            "rationale": "This molecule has excellent synthetic accessibility (SA score 2.61) and forms hydrogen bonds with SER205, THR211, and GLN79. The carboxylic acid group likely forms salt bridges with basic residues, while the fluorophenyl group enhances binding through halogen interactions. The pyrimidine ring provides a rigid scaffold with hydrogen bond acceptors.",
            "structure": {
               "smiles": "CC(C)CNC1=NC=CC(=N1)CN(C(=O)C2=CC(C(=O)O)=CC3=CC(F)=CC=C23)CCC"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.46,
               "logP": 2.44,
               "qed": 0.45,
               "sas": 2.69
            },
            "friendlyId": "AI:I1:N7:G0",
            "rationale": "This compound has good synthetic accessibility (SA score 2.69) and forms multiple hydrogen bonds with key residues. The sulfonamide group serves as a hydrogen bond donor/acceptor, while the imidazopyrimidine core provides a rigid scaffold with multiple interaction points. The pyridine ring likely interacts with acidic residues in the binding site.",
            "structure": {
               "smiles": "NS(=O)(=O)C1=CC=C(NC2=NC(NCC3=CC=CN=C3)=CN4C=CN=C24)C=C1C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.11,
               "logP": 3.82,
               "qed": 0.73,
               "sas": 3.61
            },
            "friendlyId": "AI:I1:N8:G0",
            "rationale": "This purine derivative has excellent drug-likeness (QED 0.73) and forms a strong pi-stacking interaction with TRP80. The molecule contains a chiral center with a hydroxymethyl group that forms hydrogen bonds with THR81. The phenyl groups occupy hydrophobic pockets, while the purine scaffold provides a rigid core with multiple hydrogen bond acceptors.",
            "structure": {
               "smiles": "CN1C=NC2=C(C3=CC=CC=C3)N=C(N[C@H1](CO)C4=CC=CC=C4)N2C1C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.03,
               "logP": 4.16,
               "qed": 0.47,
               "sas": 2.76
            },
            "friendlyId": "AI:I1:N9:G0",
            "rationale": "This polyphenolic compound forms multiple hydrogen bonds through its hydroxyl groups with SER205, THR211, TYR272, and GLN79. The acetamide group provides additional hydrogen bonding capability. The molecule has good synthetic accessibility (SA score 2.76) and a rigid naphthalene core that enables pi-stacking with TRP80.",
            "structure": {
               "smiles": "CC1=CC(O)=CC(O)=C1C2=CC(C)=C3C(C)=CC(NC(C)=O)=C(O)C(O)=C23"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.57,
               "logP": 1.73,
               "qed": 0.67,
               "sas": 3.87
            },
            "friendlyId": "AI:I1:N10:G0",
            "rationale": "This adenosine-like compound has good drug-likeness (QED 0.67) and forms multiple hydrogen bonds with key residues. The purine scaffold provides a rigid core with multiple hydrogen bond donors/acceptors. The chloro-substituted deoxyribose-like moiety with a phenyl substituent occupies a hydrophobic pocket while maintaining good water solubility (logP 1.73).",
            "structure": {
               "smiles": "NC1=NC=NC2=C1N=CN2[C@H1]CO[C@@H1]([C@H1](O)C3=CC=CC=C3)Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -11.75,
               "logP": 3.62,
               "molecularWeight": 545.51,
               "plipInteractions": "H-bonds with ASN204, SER205, THR211, ASP292; Hydrophobic with LEU264, VAL270, TYR272, GLN79",
               "qed": 0.46,
               "sas": 4.05
            },
            "friendlyId": "MC:I1:N1:G1",
            "parentFriendlyId": "AI:I1:N1:G0",
            "rationale": "Modified AI:I1:N1:G0 by replacing the acetamide with a hydroxyacetamide group to improve hydrogen bonding with key residues. This modification improved the docking score from -11.20 to -11.75 kcal/mol and increased the number of hydrogen bonds with binding site residues, particularly with ASN204, SER205, THR211, and ASP292.",
            "structure": {
               "smiles": "CC(O)NCC(N1C(=O)CN2CCC(C3=CC=CC4=C3CCC4)CC2)C(=O)NC1C5=C(Cl)C=CC=C5Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -11.41,
               "logP": 6.56,
               "molecularWeight": 527.63,
               "plipInteractions": "H-bonds with TYR272, ALA58, LEU78; Hydrophobic with LEU210, LEU264, VAL270, TYR272, GLN79, TRP80; Pi-stacking with TRP80",
               "qed": 0.26,
               "sas": 2.58
            },
            "friendlyId": "MC:I1:N2:G1",
            "parentFriendlyId": "DA:I1:N5:G0",
            "rationale": "Modified DA:I1:N5:G0 by adding a hydroxyl group to the terminal phenyl ring to improve hydrogen bonding and slightly reduce lipophilicity. While the docking score decreased slightly from -13.56 to -11.41 kcal/mol, the modification improved hydrogen bonding with TYR272 and ALA58, and reduced the logP from 6.86 to 6.56.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(F)cc4nc3-c3ccc(O)cc3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -12.84,
               "logP": 6.74,
               "molecularWeight": 641.8,
               "plipInteractions": "H-bonds with THR211, SER56, TRP80; Hydrophobic with LEU202, LEU210, LEU264, VAL270, TYR272, ILE290, ASN53, LEU78, TRP80",
               "qed": 0.21,
               "sas": 2.86
            },
            "friendlyId": "MC:I1:N3:G1",
            "parentFriendlyId": "DA:I1:N5:G0",
            "rationale": "Modified DA:I1:N5:G0 by adding a methylpiperazine group to improve solubility while maintaining strong binding. The docking score (-12.84 kcal/mol) remains excellent, and the modification adds a basic nitrogen that can improve solubility. The molecule forms key hydrogen bonds with THR211, SER56, and TRP80.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(F)cc4nc3-c3ccc(CN4CCN(C)CC4)cc3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.33,
               "logP": 3.01,
               "molecularWeight": 392.89,
               "plipInteractions": "H-bonds with ASN204, SER205, HIS207, ASP292; Hydrophobic with LEU210, LEU264, LYS268, TYR272, ILE290, TRP80; Pi-stacking with TRP80",
               "qed": 0.65,
               "sas": 3.52
            },
            "friendlyId": "MC:I1:N4:G1",
            "parentFriendlyId": "AI:I1:N5:G0",
            "rationale": "Modified AI:I1:N5:G0 by replacing the chloropiperidine with a methoxypiperidine and adding a carbamate group to the hydroxyethyl chain. These modifications improved the docking score from -9.83 to -10.33 kcal/mol, maintained excellent drug-likeness (QED: 0.65), and enhanced hydrogen bonding with key residues including ASN204, SER205, HIS207, and ASP292.",
            "structure": {
               "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCOC(=O)N"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.16,
               "logP": 2.68,
               "molecularWeight": 402.5,
               "plipInteractions": "H-bonds with ASN204, SER205, HIS207, THR211, ASN54; Hydrophobic with LEU210, LEU264, TYR272, TRP80; Pi-stacking with TRP80",
               "qed": 0.65,
               "sas": 3.43
            },
            "friendlyId": "MC:I1:N5:G1",
            "parentFriendlyId": "MC:I1:N4:G1",
            "rationale": "Further modified MC:I1:N4:G1 by adding a methyl group to the carbamate to improve metabolic stability. The docking score remains good at -10.16 kcal/mol, and the modification maintains excellent drug-likeness (QED: 0.65) while slightly reducing logP to 2.68. The molecule forms multiple hydrogen bonds with key residues and maintains pi-stacking with TRP80.",
            "structure": {
               "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCOC(=O)NC"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.71,
               "logP": 3.24,
               "molecularWeight": 547.05,
               "plipInteractions": "H-bonds with GLU298, CYS310, GLU85; Hydrophobic with PHE161, TYR272, ARG273, ASP274, THR82, ILE84",
               "qed": 0.46,
               "sas": 4.16
            },
            "friendlyId": "MC:I1:N6:G1",
            "parentFriendlyId": "AI:I1:N1:G0",
            "rationale": "Modified AI:I1:N1:G0 by adding fluorine substituents to both aromatic rings to improve binding and modulate lipophilicity. The docking score remains good at -10.71 kcal/mol, and the modification forms hydrogen bonds with GLU298, CYS310, and GLU85. The fluorine substituents can enhance metabolic stability and binding through halogen interactions.",
            "structure": {
               "smiles": "CC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(F)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.4,
               "logP": 2.39,
               "molecularWeight": 524.52,
               "plipInteractions": "H-bonds with GLN203, THR211, LYS268, TYR272; Hydrophobic with LEU210, LYS268, TRP80",
               "qed": 0.35,
               "sas": 3.73
            },
            "friendlyId": "MC:I1:N7:G1",
            "parentFriendlyId": "DA:I1:N4:G0",
            "rationale": "Modified DA:I1:N4:G0 by removing the salt form and adding a fluorine to the piperidine ring to enhance binding. While the docking score is moderate at -7.40 kcal/mol, the modification forms hydrogen bonds with GLN203, THR211, LYS268, and TYR272. The fluorine substituent can enhance metabolic stability and binding through halogen interactions with LYS268.",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(C(=O)N[C@@H]3CC(F)CNCC3NC(=O)c3ccncc3)cc2)c1F"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -14.86,
               "logP": 6.07,
               "molecularWeight": 666.79,
               "plipInteractions": "H-bonds with SER205, SER56, GLN59, GLN61, LEU78, TRP80; Hydrophobic with LEU210, LEU264, GLN59, LEU78, GLN79, TRP80; Pi-stacking with TRP80",
               "qed": 0.14,
               "sas": 3.24
            },
            "friendlyId": "MC:I2:N1:G2",
            "parentFriendlyId": "DA:I1:N5:G0",
            "rationale": "This hybrid molecule combines the benzoquinazoline core with pyrazole and aminopyridine elements to achieve exceptional binding affinity (-14.86 kcal/mol). The addition of polar groups (hydroxyl on pyrazole linker, amino on pyridine) improves hydrogen bonding with key residues while reducing lipophilicity compared to the parent compound. The molecule forms critical interactions with TRP80 (pi-stacking and hydrogen bond) and multiple hydrogen bonds with SER205, SER56, GLN59, and LEU78.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(NC5=CC(C)=NN5CCO)cc4nc3-c3ccnc(N)c3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -12.5,
               "logP": 5.32,
               "molecularWeight": 588.72,
               "plipInteractions": "H-bonds with THR211, ASP292, ASN54, ALA58, GLN79, TRP80; Hydrophobic with LEU210, LEU264, LYS268, VAL270, TYR272, ILE290, ASP292, ALA58, GLN79, TRP80; Pi-stacking with TRP80; Pi-cation with TRP80",
               "qed": 0.25,
               "sas": 3.0
            },
            "friendlyId": "MC:I2:N2:G2",
            "parentFriendlyId": "DA:I1:N5:G0",
            "rationale": "This modification of the benzoquinazoline scaffold replaces a phenyl ring with a pyrazole and introduces a dimethylaminoethyl side chain to improve solubility while maintaining strong binding (-12.5 kcal/mol). The logP is significantly reduced from 6.86 to 5.32 compared to the parent compound. The molecule forms critical interactions with TRP80 (pi-stacking, hydrogen bond, and pi-cation) and multiple hydrogen bonds with THR211, ASP292, ASN54, and ALA58.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3cnn(CCN(C)C)c3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.97,
               "logP": 4.64,
               "molecularWeight": 604.72,
               "plipInteractions": "H-bonds with GLN203, THR211, LYS268, LEU78, TRP80; Hydrophobic with LEU202, LYS268, VAL270, TRP80; Pi-stacking with TRP80",
               "qed": 0.21,
               "sas": 3.62
            },
            "friendlyId": "MC:I2:N3:G3",
            "parentFriendlyId": "MC:I2:N2:G2",
            "rationale": "This further optimization of the benzoquinazoline scaffold introduces a hydroxyl group to the dimethylaminoethyl side chain, significantly reducing lipophilicity (logP 4.64) while maintaining good binding affinity (-10.97 kcal/mol). The additional hydroxyl group improves hydrogen bonding with binding site residues and enhances solubility. The molecule maintains critical interactions with TRP80 (pi-stacking and hydrogen bond) and forms hydrogen bonds with GLN203, THR211, LYS268, and LEU78.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3cnn(CC(O)N(C)C)c3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -14.03,
               "logP": 7.04,
               "molecularWeight": 621.75,
               "plipInteractions": "H-bonds with TYR18, SER205, ARG273, CYS310, GLN79; Hydrophobic with LEU210, LEU264, TYR272, ASP274, ASP292, GLU298, TRP80, ILE84; Pi-stacking with TRP80; Salt bridge with ASP274",
               "qed": 0.2,
               "sas": 3.03
            },
            "friendlyId": "MC:I2:N4:G2",
            "parentFriendlyId": "DA:I1:N5:G0",
            "rationale": "This hybrid molecule combines the benzoquinazoline core with pyrazole and pyridine elements to achieve excellent binding affinity (-14.03 kcal/mol). The molecule forms critical interactions with TRP80 (pi-stacking) and multiple hydrogen bonds with SER205, ARG273, CYS310, and GLN79. While the logP remains high (7.04), the molecule demonstrates exceptional binding affinity and forms a salt bridge with ASP274, which could enhance binding stability.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(NC5=CC(C)=NN5C)cc4nc3-c3ccncc3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.59,
               "logP": 2.41,
               "molecularWeight": 404.49,
               "plipInteractions": "H-bonds with ASN204, SER205, HIS207, THR211, ASP292, THR82; Hydrophobic with LEU264, LYS268, ASP292, TRP80; Pi-stacking with TRP80",
               "qed": 0.63,
               "sas": 3.45
            },
            "friendlyId": "MC:I2:N5:G2",
            "parentFriendlyId": "MC:I1:N4:G1",
            "rationale": "This modification of the pyridine-pyrazole scaffold replaces the carbamate with a fluoroacetamide to improve metabolic stability while maintaining good binding affinity (-10.59 kcal/mol) and excellent drug-likeness (QED 0.63). The molecule forms critical interactions with TRP80 (pi-stacking) and multiple hydrogen bonds with ASN204, SER205, HIS207, THR211, and ASP292. The logP (2.41) is in an optimal range for oral bioavailability.",
            "structure": {
               "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)CF"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.04,
               "logP": 2.94,
               "molecularWeight": 433.53,
               "plipInteractions": "H-bonds with ASN204, SER205, TYR272, GLN79; Hydrophobic with ALA212, LEU264, VAL270, ASP292, GLN79, TRP80; Pi-stacking with TRP80",
               "qed": 0.48,
               "sas": 3.83
            },
            "friendlyId": "MC:I2:N6:G3",
            "parentFriendlyId": "MC:I2:N5:G2",
            "rationale": "This further optimization of the pyridine-pyrazole scaffold replaces the fluoroacetamide with a fluoromethylurea to enhance hydrogen bonding capabilities while maintaining good drug-likeness (QED 0.48). The molecule forms critical interactions with TRP80 (pi-stacking) and multiple hydrogen bonds with ASN204, SER205, TYR272, and GLN79. The logP (2.94) remains in a favorable range for oral bioavailability.",
            "structure": {
               "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)NC(C)F"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.89,
               "logP": 2.81,
               "molecularWeight": 545.06,
               "plipInteractions": "H-bonds with LYS179, THR211, ARG273, ASP292, GLY294, ASN53, GLN59, LEU78, THR82; Hydrophobic with LEU210, LEU264, VAL270, VAL271, TYR272, ARG273, ASP292, ASN53, LEU78, TRP80, ILE84; Pi-stacking with TRP80; Pi-cation with ARG273; Halogen bond with ALA58",
               "qed": 0.4,
               "sas": 4.18
            },
            "friendlyId": "MC:I2:N7:G2",
            "parentFriendlyId": "MC:I1:N1:G1",
            "rationale": "This modification of the piperidine-containing scaffold introduces a hydroxyl group to the tetrahydronaphthalene moiety and replaces one chlorine with fluorine to improve drug-likeness and reduce lipophilicity (logP 2.81). The molecule forms critical interactions with TRP80 (pi-stacking) and multiple hydrogen bonds with THR211, ARG273, ASP292, ASN53, GLN59, and LEU78. The addition of the hydroxyl group enhances hydrogen bonding capabilities and improves solubility.",
            "structure": {
               "smiles": "CC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.71,
               "logP": 2.75,
               "molecularWeight": 563.05,
               "plipInteractions": "H-bonds with SER205, ASN53, GLN59, LEU78; Hydrophobic with LEU202, LYS268, TRP80; Pi-stacking with TRP80; Halogen bond with ALA58",
               "qed": 0.39,
               "sas": 4.56
            },
            "friendlyId": "MC:I2:N8:G3",
            "parentFriendlyId": "MC:I2:N7:G2",
            "rationale": "This further optimization of the piperidine-containing scaffold adds a fluorine to the tetrahydronaphthalene moiety to enhance metabolic stability. While the docking score is slightly lower (-9.71 kcal/mol), the molecule maintains good drug-likeness (QED 0.39) and favorable lipophilicity (logP 2.75). The molecule forms critical interactions with TRP80 (pi-stacking) and multiple hydrogen bonds with SER205, ASN53, GLN59, and LEU78.",
            "structure": {
               "smiles": "CC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CC(F)C4)CC2)C(=O)NC1C5=C(F)C=CC=C5Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -13.09,
               "logP": 6.09,
               "molecularWeight": 597.72,
               "plipInteractions": "H-bonds with THR211, TRP80; Hydrophobic with LEU210, LEU264, LYS268, VAL270, TYR272, ASP292, ALA58, GLN79, TRP80; Pi-stacking with TRP80; Pi-cation with TRP80",
               "qed": 0.25,
               "sas": 2.83
            },
            "friendlyId": "MC:I2:N9:G2",
            "parentFriendlyId": "DA:I1:N5:G0",
            "rationale": "This modification of the benzoquinazoline scaffold introduces a morpholine group and replaces a phenyl with a fluorophenyl to improve solubility while maintaining excellent binding affinity (-13.09 kcal/mol). The molecule forms critical interactions with TRP80 (pi-stacking, hydrogen bond, and pi-cation) and a hydrogen bond with THR211. The synthetic accessibility is excellent (SA score 2.83), making this a promising candidate for further development.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(N4CCOCC4)cc4nc3-c3ccc(F)cc3)cc2)CC1"
            }
         }
      }
   ],
   "protein_data": {
      "sequence": "MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA",
      "pdb_path": "/Users/atabeyunlu/multi_agent_paper/runs_metadata/0619_0025_VXG_sonnet-3.7_3/pdb_files/4EJN.pdb"
   }
}.The Principal Researcher will now initiate this iteration's activities based on the above directives.

---

## User

```
[{'type': 'text', 'text': "Principal Researcher, the system has provided the full context for **Iteration 2**, including your 'Comprehensive Iteration Summary and Directives for Next Iteration' (which are the directives for *this current* iteration)\n\nPlease now formally commence This iteration:\n1. Remind the primary objective of this project, what protein we target, the approach etc 2. Briefly reiterate the **absolute key objectives** for this iteration that the team must focus on, drawing from your detailed directives.\n3. If necessary, provide any very brief, final clarifying remarks or points of emphasis for the specific agents based on their roles in *this* iteration's plan.\n4. Delegate to the first agent (e.g., Medicinal Chemist or Ranking Agent, as appropriate for your plan) to begin their specific tasks for This iteration."}]
```

---

## Assistant

```
[{'type': 'text', 'text': "# Commencement of Iteration 3: Final Lead Optimization for AKT1 Inhibitor Discovery\n\n## Primary Project Objective\n\nWe are conducting an *in silico* drug discovery project to develop potent and selective AKT1 inhibitors with balanced pharmacological profiles. AKT1 (Protein Kinase B alpha) is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes including glucose metabolism, apoptosis, cell proliferation, and cell migration, making it an important target for various diseases including cancer.\n\nOur approach has been entirely computational, progressing through three iterations:\n1. **Iteration 1**: Initial screening and identification of promising scaffolds\n2. **Iteration 2**: Lead optimization focusing on three main scaffolds\n3. **Iteration 3** (Current): Final lead optimization and selection of 10 candidate molecules\n\n## Key Objectives for Iteration 3\n\nBased on our progress in Iteration 2, we must focus on the following critical objectives:\n\n1. **Finalize 10 Optimized Candidate Molecules**: Select and optimize the final set of molecules with balanced profiles across binding affinity, drug-likeness, and predicted ADMET properties.\n\n2. **Address Identified Limitations**: Specifically:\n   - Replace potentially toxic fluoroacetamide groups in the pyridine-pyrazole scaffold\n   - Reduce lipophilicity in the benzoquinazoline scaffold while maintaining binding\n   - Enhance metabolic stability in all scaffolds, particularly the piperidine-containing series\n   - Improve selectivity by targeting AKT1-specific binding site features\n\n3. **Ensure Comprehensive Evaluation**: All final molecules must have complete docking scores and other metrics to enable proper ranking and assessment of progress against our target of 10% improvement over the best known active compound.\n\n4. **Balance Representation Across Scaffolds**: Ensure our final selection includes optimized representatives from all three promising scaffolds: pyridine-pyrazole, benzoquinazoline, and piperidine-containing.\n\n## Specific Directives for Participating Agents\n\n### For Medicinal Chemist:\nYou are tasked with making final modifications to optimize our lead compounds. Please focus on:\n- Replacing the potentially toxic fluoroacetamide in MC:I2:N5:G2 with safer bioisosteres\n- Further reducing lipophilicity in the benzoquinazoline scaffold (MC:I2:N3:G3, MC:I2:N2:G2)\n- Enhancing metabolic stability in the piperidine-containing scaffold (MC:I2:N7:G2)\n- Generating at least 12 optimized compounds to allow for selection of the final 10 candidates\n- Using the VINA_REPORT tool to evaluate all modifications for docking score, drug-likeness, and other key properties\n\n### For Ranking Agent:\nYou will be responsible for:\n- Developing a comprehensive composite score incorporating docking score, drug-likeness, lipophilicity, molecular weight, synthetic accessibility, and topological polar surface area\n- Evaluating compounds based on interactions with AKT1-specific residues\n- Ranking all compounds and identifying the top 10 as final candidates\n- Providing detailed rationales for rankings, highlighting key strengths and weaknesses\n\n## Delegation to Begin Iteration 3\n\nI now invite the **Medicinal Chemist** to begin this final iteration by designing and evaluating optimized analogs of our lead compounds. Please focus on the three main scaffolds we've identified, with particular attention to addressing the metabolic liabilities and physicochemical property concerns highlighted in our directives. For each modification, please provide a clear rationale and ensure comprehensive evaluation using the VINA_REPORT tool."}]
```

---

## User

```
[{'type': 'text', 'text': 'Medicinal Chemist, for iteration 3/3, review the molecules presented. Propose and execute modifications to improve them, then evaluate the modified molecules using your tools. Share your work. Follow the molecule sharing format.When you are reference the SMILES and its Friendly ID when you are thinking a enhancement of a molecule.You can do multiple modifications at once to send for evaluation to the VINA_REPORT tool.'}]
```

---

## Assistant

```
[{'type': 'text', 'text': "# Medicinal Chemist - Iteration 3 Analysis and Optimization Plan\n\nThank you for the directive. I'll now begin the final lead optimization phase for our AKT1 inhibitor project. Based on the Principal Researcher's guidance, I'll focus on optimizing our three main scaffolds while addressing specific concerns about metabolic stability, toxicity, and physicochemical properties.\n\n## Initial Analysis of Lead Compounds\n\nLet me first analyze our top compounds from Iteration 2 to identify specific optimization opportunities:\n\n### Pyridine-Pyrazole Scaffold\n**MC:I2:N5:G2** (SMILES: `CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)CF`)\n- Excellent binding (-10.59 kcal/mol) and drug-likeness (QED 0.63)\n- **Key concern**: Contains potentially toxic fluoroacetamide group\n- **Optimization goal**: Replace with safer bioisosteres while maintaining H-bonding\n\n**MC:I1:N4:G1** (SMILES: `CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCOC(=O)N`)\n- Good binding (-10.33 kcal/mol) and excellent drug-likeness (QED 0.65)\n- **Optimization goal**: Enhance metabolic stability of the carbamate group\n\n### Benzoquinazoline Scaffold\n**MC:I2:N3:G3** (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3cnn(CC(O)N(C)C)c3)cc2)CC1`)\n- Good binding (-10.97 kcal/mol) but suboptimal drug-likeness (QED 0.21)\n- **Key concern**: High molecular weight (604.72) and potential metabolic liabilities\n- **Optimization goal**: Simplify structure while maintaining key interactions\n\n**MC:I2:N2:G2** (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3cnn(CCN(C)C)c3)cc2)CC1`)\n- Excellent binding (-12.50 kcal/mol) but suboptimal drug-likeness (QED 0.25)\n- **Optimization goal**: Further reduce lipophilicity and improve metabolic stability\n\n### Piperidine-Containing Scaffold\n**MC:I2:N7:G2** (SMILES: `CC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5Cl`)\n- Good binding (-10.89 kcal/mol) and acceptable drug-likeness (QED 0.40)\n- **Key concern**: Mixed halogen substitution pattern\n- **Optimization goal**: Optimize halogenation strategy and enhance metabolic stability\n\n## Optimization Strategy\n\nI'll now design and evaluate optimized analogs for each scaffold, focusing on:\n1. Replacing potentially toxic groups with safer bioisosteres\n2. Reducing lipophilicity and molecular weight\n3. Enhancing metabolic stability\n4. Improving selectivity for AKT1\n\nLet's begin with the first set of modifications:\n\n### First Round of Modifications\n\n#### 1. Pyridine-Pyrazole Scaffold Optimization\n\nFor MC:I2:N5:G2, I'll replace the potentially toxic fluoroacetamide with safer bioisosteres:\n\n**Modification 1A**: Replace fluoroacetamide with oxadiazole (metabolically stable bioisostere)\n```\nCC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCN1C=NOC1\n```\n\n**Modification 1B**: Replace fluoroacetamide with cyclopropylcarboxamide (metabolically stable)\n```\nCC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)C1CC1\n```\n\n**Modification 1C**: Replace fluoroacetamide with methylisoxazole-carboxamide\n```\nCC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)c1cc(C)on1\n```\n\n#### 2. Benzoquinazoline Scaffold Optimization\n\nFor MC:I2:N3:G3, I'll simplify the structure and reduce molecular weight:\n\n**Modification 2A**: Replace dimethylaminoethanol with morpholine (reduces basicity, improves metabolic stability)\n```\nOc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3cnn(CCN4CCOCC4)c3)cc2)CC1\n```\n\n**Modification 2B**: Replace pyrazole with oxazole and simplify linker (reduces MW)\n```\nOc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3coc(N4CCOCC4)n3)cc2)CC1\n```\n\n#### 3. Piperidine-Containing Scaffold Optimization\n\nFor MC:I2:N7:G2, I'll optimize the halogenation pattern:\n\n**Modification 3A**: Replace mixed halogens with difluoro substitution (more consistent metabolism)\n```\nCC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5F\n```\n\n**Modification 3B**: Add methyl to hydroxyl group (blocks metabolism) and optimize halogenation\n```\nCC(OC)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5F\n```\n\nLet me now evaluate these modifications using the VINA_REPORT tool:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': "Based on the results from the first round of modifications, I'll now analyze the performance of each compound and design a second round of optimizations:\n\n## Analysis of First Round Results\n\n### Pyridine-Pyrazole Scaffold Modifications:\n\n1. **Modification 1A** (Oxadiazole replacement, SMILES: `CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCN1C=NOC1`):\n   - Docking score: -9.77 kcal/mol\n   - QED: 0.74 (excellent drug-likeness)\n   - LogP: 2.56 (optimal lipophilicity)\n   - Key interactions: H-bonds with ASN204, SER205, HIS207; Pi-stacking with TRP80\n   - Assessment: Excellent drug-likeness but slightly reduced binding compared to parent\n\n2. **Modification 1B** (Cyclopropylcarboxamide, SMILES: `CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)C1CC1`):\n   - Docking score: -10.67 kcal/mol (improved over parent)\n   - QED: 0.62 (very good drug-likeness)\n   - LogP: 2.85 (optimal lipophilicity)\n   - Key interactions: H-bonds with ASN204, SER205, HIS207; Pi-stacking with TRP80\n   - Assessment: Excellent balance of binding and drug-likeness, metabolically stable\n\n3. **Modification 1C** (Methylisoxazole-carboxamide, SMILES: `CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)c1cc(C)on1`):\n   - Docking score: -11.79 kcal/mol (significantly improved over parent)\n   - QED: 0.48 (good drug-likeness)\n   - LogP: 3.05 (optimal lipophilicity)\n   - Key interactions: H-bonds with ASN204, SER205, THR211, TYR272, THR82; Pi-stacking with TRP80\n   - Assessment: Excellent binding with good drug-likeness, forms additional H-bonds\n\n### Benzoquinazoline Scaffold Modifications:\n\n4. **Modification 2A** (Morpholine replacement, SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3cnn(CCN4CCOCC4)c3)cc2)CC1`):\n   - Docking score: -11.89 kcal/mol (good binding)\n   - QED: 0.24 (suboptimal drug-likeness)\n   - LogP: 5.09 (improved over parent but still high)\n   - Key interactions: H-bonds with ASP274, GLY294, LEU78, TRP80, THR82; Pi-cation with LYS179\n   - Assessment: Good binding but still has high MW (630.75) and suboptimal drug-likeness\n\n5. **Modification 2B** (Oxazole replacement, SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3coc(N4CCOCC4)n3)cc2)CC1`):\n   - Docking score: -13.42 kcal/mol (excellent binding)\n   - QED: 0.26 (suboptimal drug-likeness)\n   - LogP: 5.39 (still high)\n   - Key interactions: Multiple H-bonds with GLN203, SER205, LYS268, ASP274, ASN279, PHE293, THR82; Pi-stacking with TRP80\n   - Assessment: Excellent binding but still has high MW (603.68) and suboptimal drug-likeness\n\n### Piperidine-Containing Scaffold Modifications:\n\n6. **Modification 3A** (Difluoro substitution, SMILES: `CC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5F`):\n   - Docking score: -10.15 kcal/mol (good binding)\n   - QED: 0.41 (acceptable drug-likeness)\n   - LogP: 2.29 (optimal lipophilicity)\n   - Key interactions: H-bonds with GLN203, THR211, ASN53; Hydrophobic with LEU264, VAL270, TYR272\n   - Assessment: Good balance of binding and drug-likeness, consistent halogenation pattern\n\n7. **Modification 3B** (Methoxy protection, SMILES: `CC(OC)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5F`):\n   - Docking score: -10.46 kcal/mol (good binding)\n   - QED: 0.44 (acceptable drug-likeness)\n   - LogP: 2.95 (optimal lipophilicity)\n   - Key interactions: H-bonds with THR211, ASP274, GLY294, ASN54, GLN79; Pi-cation with ARG273\n   - Assessment: Good balance of binding and drug-likeness, metabolically protected hydroxyl\n\n## Second Round of Modifications\n\nBased on the results from the first round, I'll now design additional compounds focusing on the most promising leads:\n\n### Pyridine-Pyrazole Scaffold (Further Optimizations):\n\n**Modification 4**: Based on the success of Modification 1C, I'll explore a similar isoxazole bioisostere with additional H-bond capability:\n```\nCC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)c1noc(N)n1\n```\n\n**Modification 5**: Optimize the methoxypiperidine group in Modification 1B for improved binding:\n```\nCC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC(F)F)C3)=C1CCNC(=O)C1CC1\n```\n\n### Benzoquinazoline Scaffold (Simplification):\n\n**Modification 6**: Significantly simplify the structure to reduce MW while maintaining key interactions:\n```\nOc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3ccn(C)n3)cc2)CC1\n```\n\n**Modification 7**: Replace the quinazoline core with a smaller isostere to reduce MW and lipophilicity:\n```\nOc1nc2ccccc2n1C1CCN(Cc2ccc(-c3ncc(O)cc3-c3cnn(CCN4CCOCC4)c3)cc2)CC1\n```\n\n### Piperidine-Containing Scaffold (Stereochemical Optimization):\n\n**Modification 8**: Specify stereochemistry and add a methyl group to block metabolism:\n```\nC[C@H](O)NCC(N1C(=O)CN2CC[C@H](C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5F\n```\n\n**Modification 9**: Introduce a cyclopropyl group to enhance metabolic stability:\n```\nCC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(OC4CC4)C5=C3CCC5)CC2)C(=O)NC1C6=C(F)C=CC=C6F\n```\n\nLet me now evaluate these additional modifications using the VINA_REPORT tool:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': "Based on the results from both rounds of modifications, I'll now design a final set of compounds to complete our optimization process. I'll focus on further refining the most promising leads from the previous rounds:\n\n### Third Round of Modifications\n\n#### Pyridine-Pyrazole Scaffold (Final Optimization):\n\n**Modification 10**: Combine the best features of Modification 1B and 1C to optimize binding and drug-likeness:\n```\nCC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)c1cc(C)no1\n```\n\n**Modification 11**: Optimize the linker region of Modification 1B to enhance binding:\n```\nCC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)N1CC1\n```\n\n#### Benzoquinazoline Scaffold (Final Optimization):\n\n**Modification 12**: Further simplify Modification 2B to reduce MW while maintaining key interactions:\n```\nOc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3coc(C)n3)cc2)CC1\n```\n\n**Modification 13**: Optimize Modification 7 to improve drug-likeness:\n```\nOc1nc2ccccc2n1C1CCN(Cc2ccc(-c3ncc(O)cc3-c3cnn(CCO)c3)cc2)CC1\n```\n\n#### Piperidine-Containing Scaffold (Final Optimization):\n\n**Modification 14**: Optimize Modification 9 to enhance binding interactions:\n```\nCC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(OC4CC4)C5=C3CCC5F)CC2)C(=O)NC1C6=C(F)C=CC=C6F\n```\n\n**Modification 15**: Introduce a solubilizing group to Modification 8:\n```\nC[C@H](O)NCC(N1C(=O)CN2CC[C@H](C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=C(N(C)C)C=C5F\n```\n\nLet me now evaluate these final modifications using the VINA_REPORT tool:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': 'Now that I\'ve completed three rounds of modifications and evaluations, I\'ll select the top 10 compounds from all the molecules we\'ve generated based on their overall profiles. I\'ll present these as our final optimized candidates for AKT1 inhibition.\n\n## Final Selection of 10 Optimized AKT1 Inhibitor Candidates\n\n<molecules>\n{\n    "current_iteration": 3,\n    "molecules": [\n        {\n            "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)c1cc(C)on1",\n            "friendly_id": "MC:I3:N1:G3",\n            "source": "MC:I2:N5:G2",\n            "cycle": 1,\n            "status": "modified",\n            "iteration": 3,\n            "agent": "Medicinal Chemist",\n            "metrics": {\n                "docking": "-11.79",\n                "qed": "0.48",\n                "sa_score": "3.42",\n                "logp": "3.05",\n                "molecular_weight": "453.55",\n                "plip_interactions": "H-bonds with ASN204, SER205, THR211, TYR272, THR82; Hydrophobic with LEU210, LEU264, VAL270, TYR272, ILE290, TRP80; Pi-stacking with TRP80"\n            },\n            "rationale": "Replaced the potentially toxic fluoroacetamide in MC:I2:N5:G2 with a methylisoxazole-carboxamide bioisostere. This modification maintains the hydrogen bonding capabilities while eliminating the metabolic liability of the fluoroacetamide. The compound shows excellent binding affinity (-11.79 kcal/mol) with multiple hydrogen bonds to key residues and maintains good drug-likeness (QED 0.48) with optimal lipophilicity (logP 3.05)."\n        },\n        {\n            "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)c1cc(C)no1",\n            "friendly_id": "MC:I3:N2:G3",\n            "source": "MC:I2:N5:G2",\n            "cycle": 1,\n            "status": "modified",\n            "iteration": 3,\n            "agent": "Medicinal Chemist",\n            "metrics": {\n                "docking": "-12.41",\n                "qed": "0.48",\n                "sa_score": "3.46",\n                "logp": "3.05",\n                "molecular_weight": "453.55",\n                "plip_interactions": "H-bonds with ASN204, SER205, THR211, ASP274, ASP292, GLY294, THR82; Hydrophobic with LEU210, LEU264, VAL270, TYR272, ILE290, TRP80; Pi-stacking with TRP80"\n            },\n            "rationale": "Further optimized the pyridine-pyrazole scaffold by replacing the fluoroacetamide with an isoxazole bioisostere in a different orientation. This modification significantly improved binding affinity (-12.41 kcal/mol) compared to the parent compound while maintaining good drug-likeness (QED 0.48) and optimal lipophilicity (logP 3.05). The compound forms additional hydrogen bonds with ASP292 and GLY294, enhancing binding stability."\n        },\n        {\n            "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)N1CC1",\n            "friendly_id": "MC:I3:N3:G3",\n            "source": "MC:I2:N5:G2",\n            "cycle": 1,\n            "status": "modified",\n            "iteration": 3,\n            "agent": "Medicinal Chemist",\n            "metrics": {\n                "docking": "-10.83",\n                "qed": "0.60",\n                "sa_score": "3.32",\n                "logp": "2.35",\n                "molecular_weight": "413.53",\n                "plip_interactions": "H-bonds with ASN204, SER205, HIS207, THR211; Hydrophobic with LEU264, LYS268, TYR272, TRP80; Pi-stacking with TRP80"\n            },\n            "rationale": "Replaced the fluoroacetamide in MC:I2:N5:G2 with a cyclopropylurea group to improve metabolic stability and drug-likeness. This modification resulted in excellent drug-likeness (QED 0.60) and optimal lipophilicity (logP 2.35) while maintaining good binding affinity (-10.83 kcal/mol). The compound forms key hydrogen bonds with ASN204, SER205, HIS207, and THR211, and maintains pi-stacking with TRP80."\n        },\n        {\n            "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC(F)F)C3)=C1CCNC(=O)C1CC1",\n            "friendly_id": "MC:I3:N4:G3",\n            "source": "MC:I1:N4:G1",\n            "cycle": 1,\n            "status": "modified",\n            "iteration": 3,\n            "agent": "Medicinal Chemist",\n            "metrics": {\n                "docking": "-10.52",\n                "qed": "0.54",\n                "sa_score": "3.49",\n                "logp": "3.44",\n                "molecular_weight": "448.52",\n                "plip_interactions": "H-bonds with SER205, HIS207, THR211; Halogen bond with THR211; Hydrophobic with ASN204, LEU264, LYS268, VAL270, TYR272, GLN79, TRP80; Pi-stacking with TRP80"\n            },\n            "rationale": "Modified the pyridine-pyrazole scaffold by replacing the methoxy group with a difluoromethoxy group to enhance metabolic stability and introducing a cyclopropylcarboxamide to replace the carbamate. This modification maintains good binding affinity (-10.52 kcal/mol) while improving drug-likeness (QED 0.54). The difluoromethoxy group forms a halogen bond with THR211, enhancing binding stability."\n        },\n        {\n            "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3coc(N4CCOCC4)n3)cc2)CC1",\n            "friendly_id": "MC:I3:N5:G3",\n            "source": "MC:I2:N3:G3",\n            "cycle": 1,\n            "status": "modified",\n            "iteration": 3,\n            "agent": "Medicinal Chemist",\n            "metrics": {\n                "docking": "-13.42",\n                "qed": "0.26",\n                "sa_score": "3.17",\n                "logp": "5.39",\n                "molecular_weight": "603.68",\n                "plip_interactions": "H-bonds with GLN203, SER205, LYS268, ASP274, ASN279, PHE293, THR82; Hydrophobic with LEU202, LYS268, VAL270, TYR272, GLN79, TRP80; Pi-stacking with TRP80; Pi-cation with LYS179"\n            },\n            "rationale": "Simplified the benzoquinazoline scaffold by replacing the pyrazole with an oxazole and introducing a morpholine group to improve solubility. This modification resulted in excellent binding affinity (-13.42 kcal/mol) with multiple hydrogen bonds to key residues. While the molecular weight (603.68) and lipophilicity (logP 5.39) remain high, the compound shows improved synthetic accessibility (SA score 3.17) compared to previous benzoquinazoline derivatives."\n        },\n        {\n            "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3ncc(O)cc3-c3cnn(CCN4CCOCC4)c3)cc2)CC1",\n            "friendly_id": "MC:I3:N6:G3",\n            "source": "MC:I2:N3:G3",\n            "cycle": 1,\n            "status": "modified",\n            "iteration": 3,\n            "agent": "Medicinal Chemist",\n            "metrics": {\n                "docking": "-12.53",\n                "qed": "0.28",\n                "sa_score": "3.00",\n                "logp": "4.54",\n                "molecular_weight": "579.71",\n                "plip_interactions": "H-bonds with ASN204, SER205, ALA58, GLN79; Hydrophobic with LEU264, VAL270, ASN53, TRP80; Pi-stacking with TRP80"\n            },\n            "rationale": "Significantly modified the benzoquinazoline scaffold by replacing the quinazoline core with a smaller pyridine isostere to reduce molecular weight and lipophilicity. This modification maintained excellent binding affinity (-12.53 kcal/mol) while reducing logP from 5.32 to 4.54. The compound forms key hydrogen bonds with ASN204, SER205, ALA58, and GLN79, and maintains pi-stacking with TRP80."\n        },\n        {\n            "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3ccn(C)n3)cc2)CC1",\n            "friendly_id": "MC:I3:N7:G3",\n            "source": "MC:I2:N3:G3",\n            "cycle": 1,\n            "status": "modified",\n            "iteration": 3,\n            "agent": "Medicinal Chemist",\n            "metrics": {\n                "docking": "-11.92",\n                "qed": "0.31",\n                "sa_score": "2.89",\n                "logp": "5.30",\n                "molecular_weight": "531.62",\n                "plip_interactions": "H-bonds with GLN203, SER205, LYS268, ARG273, TRP80; Hydrophobic with LEU264, VAL270, TYR272, ASN54, PHE55, ILE84, TRP80; Pi-stacking with TRP80; Pi-cation with ARG273"\n            },\n            "rationale": "Simplified the benzoquinazoline scaffold by replacing the pyrazole with a methylpyrazole to reduce molecular weight while maintaining key interactions. This modification resulted in good binding affinity (-11.92 kcal/mol) with improved synthetic accessibility (SA score 2.89). The compound forms hydrogen bonds with GLN203, SER205, LYS268, ARG273, and TRP80, and maintains pi-stacking with TRP80."\n        },\n        {\n            "smiles": "CC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(OC4CC4)C5=C3CCC5F)CC2)C(=O)NC1C6=C(F)C=CC=C6F",\n            "friendly_id": "MC:I3:N8:G3",\n            "source": "MC:I2:N7:G2",\n            "cycle": 1,\n            "status": "modified",\n            "iteration": 3,\n            "agent": "Medicinal Chemist",\n            "metrics": {\n                "docking": "-11.48",\n                "qed": "0.39",\n                "sa_score": "4.60",\n                "logp": "3.60",\n                "molecular_weight": "586.66",\n                "plip_interactions": "H-bonds with SER205; Hydrophobic with LYS268, TYR272, ASP274, ASP292, TRP80, ILE84; Halogen bond with ARG273; Salt bridge with ASP292"\n            },\n            "rationale": "Enhanced the piperidine-containing scaffold by introducing a cyclopropylmethoxy group to block metabolism of the hydroxyl and adding a fluorine to the tetrahydronaphthalene to improve metabolic stability. This modification resulted in good binding affinity (-11.48 kcal/mol) with optimal lipophilicity (logP 3.60). The compound forms a key hydrogen bond with SER205 and a halogen bond with ARG273, enhancing binding stability."\n        },\n        {\n            "smiles": "CC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5F",\n            "friendly_id": "MC:I3:N9:G3",\n            "source": "MC:I2:N7:G2",\n            "cycle": 1,\n            "status": "modified",\n            "iteration": 3,\n            "agent": "Medicinal Chemist",\n            "metrics": {\n                "docking": "-10.15",\n                "qed": "0.41",\n                "sa_score": "4.17",\n                "logp": "2.29",\n                "molecular_weight": "528.60",\n                "plip_interactions": "H-bonds with GLN203, SER205, THR211, THR291, ASN53; Hydrophobic with LEU210, LEU264, VAL270, TYR272, ASP292, ASN53, GLN79, TRP80"\n            },\n            "rationale": "Optimized the piperidine-containing scaffold by replacing the mixed halogen substitution with a consistent difluoro pattern to improve metabolic stability. This modification maintained good binding affinity (-10.15 kcal/mol) while significantly reducing lipophilicity (logP 2.29). The compound forms multiple hydrogen bonds with GLN203, SER205, THR211, THR291, and ASN53, and maintains hydrophobic interactions with TRP80."\n        },\n        {\n            "smiles": "CC(OC)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5F",\n            "friendly_id": "MC:I3:N10:G3",\n            "source": "MC:I2:N7:G2",\n            "cycle": 1,\n            "status": "modified",\n            "iteration": 3,\n            "agent": "Medicinal Chemist",\n            "metrics": {\n                "docking": "-10.46",\n                "qed": "0.44",\n                "sa_score": "4.25",\n                "logp": "2.95",\n                "molecular_weight": "542.63",\n                "plip_interactions": "H-bonds with THR211, ASP274, GLY294, ASN54, GLN79; Hydrophobic with LEU264, VAL270, VAL271, TYR272, ARG273, ASP292, ASN54, PHE55, TRP80, ILE84; Pi-cation with ARG273; Halogen bond with TYR272"\n            },\n            "rationale": "Modified the piperidine-containing scaffold by adding a methoxy group to the hydroxyl to block metabolism and replacing the mixed halogen substitution with a consistent difluoro pattern. This modification maintained good binding affinity (-10.46 kcal/mol) with improved drug-likeness (QED 0.44) and optimal lipophilicity (logP 2.95). The compound forms multiple hydrogen bonds with key residues and a halogen bond with TYR272."\n        }\n    ],\n    "summaries": [\n        {\n            "iteration": 3,\n            "summary": "In this final iteration, I focused on optimizing our lead compounds from the three main scaffolds identified in previous iterations. For the pyridine-pyrazole scaffold, I replaced the potentially toxic fluoroacetamide group with safer bioisosteres such as isoxazole and cyclopropylurea, resulting in compounds with excellent binding affinity (up to -12.41 kcal/mol) and drug-likeness (QED up to 0.60). For the benzoquinazoline scaffold, I simplified the structure to reduce molecular weight and lipophilicity while maintaining strong binding, resulting in compounds with excellent binding affinity (up to -13.42 kcal/mol) and improved synthetic accessibility. For the piperidine-containing scaffold, I optimized the halogenation pattern and introduced metabolically stable groups, resulting in compounds with good binding affinity (up to -11.48 kcal/mol) and optimal lipophilicity. The final set of 10 compounds represents a diverse collection of optimized AKT1 inhibitors with balanced profiles of binding affinity, drug-likeness, and predicted ADMET properties."\n        }\n    ]\n}\n</molecules>\n\n## Comprehensive Analysis of Final Optimized Compounds\n\n### 1. Pyridine-Pyrazole Scaffold Optimization (MC:I3:N1:G3 to MC:I3:N4:G3)\n\nThe pyridine-pyrazole scaffold emerged as our most promising series, offering an excellent balance of potency and drug-likeness. Key achievements include:\n\n- **Elimination of Metabolic Liabilities**: Successfully replaced the potentially toxic fluoroacetamide group with safer bioisosteres (isoxazole, cyclopropylurea) that maintain hydrogen bonding capabilities.\n- **Enhanced Binding Affinity**: Achieved binding scores up to -12.41 kcal/mol (MC:I3:N2:G3), representing a significant improvement over the parent compound.\n- **Excellent Drug-Likeness**: Maintained or improved QED scores (up to 0.60 for MC:I3:N3:G3) while keeping molecular weight below 455 Da.\n- **Optimal Physicochemical Properties**: All compounds have logP values in the ideal range (2.35-3.44) for oral bioavailability.\n- **Key Binding Interactions**: All compounds maintain critical interactions with TRP80 (pi-stacking) and form multiple hydrogen bonds with ASN204, SER205, and other key residues.\n\n### 2. Benzoquinazoline Scaffold Optimization (MC:I3:N5:G3 to MC:I3:N7:G3)\n\nThe benzoquinazoline scaffold provided our highest binding affinity compounds, though with challenges in drug-likeness. Key achievements include:\n\n- **Reduced Lipophilicity**: Successfully reduced logP from 6.86 (original DA:I1:N5:G0) to as low as 4.54 (MC:I3:N6:G3).\n- **Simplified Structure**: Replaced complex substituents with smaller isosteres to reduce molecular weight while maintaining key interactions.\n- **Enhanced Binding Interactions**: Achieved excellent binding scores (up to -13.42 kcal/mol for MC:I3:N5:G3) with multiple hydrogen bonds to key residues.\n- **Improved Synthetic Accessibility**: Reduced SA scores to as low as 2.89 (MC:I3:N7:G3), making these compounds more feasible for synthesis.\n\n### 3. Piperidine-Containing Scaffold Optimization (MC:I3:N8:G3 to MC:I3:N10:G3)\n\nThe piperidine-containing scaffold offered good binding with balanced physicochemical properties. Key achievements include:\n\n- **Optimized Halogenation Pattern**: Replaced mixed halogen substitution with consistent patterns to improve metabolic stability.\n- **Enhanced Metabolic Stability**: Introduced cyclopropyl and methoxy groups to block metabolism at vulnerable sites.\n- **Balanced Properties**: Achieved good binding scores (up to -11.48 kcal/mol for MC:I3:N8:G3) with acceptable drug-likeness (QED up to 0.44).\n- **Optimal Lipophilicity**: Maintained logP values in the ideal range (2.29-3.60) for oral bioavailability.\n\n### 4. Structure-Activity Relationship (SAR) Insights\n\nThrough our optimization process, we\'ve identified several key SAR insights:\n\n1. **Essential Binding Elements**:\n   - Pi-stacking interaction with TRP80 is critical for high-affinity binding across all scaffolds\n   - Hydrogen bonding with SER205 significantly enhances binding affinity\n   - Halogen bonds can provide additional binding stability\n\n2. **Optimal Substituents**:\n   - Isoxazole and cyclopropyl groups serve as excellent bioisosteres for the fluoroacetamide\n   - Methoxypiperidine provides an optimal balance of size and hydrogen bonding capability\n   - Hydroxyl groups on aromatic rings enhance hydrogen bonding and reduce lipophilicity\n\n3. **Scaffold-Specific Insights**:\n   - Pyridine-pyrazole scaffold: Optimal balance of binding and drug-likeness\n   - Benzoquinazoline scaffold: Highest binding affinity but challenges with drug-likeness\n   - Piperidine-containing scaffold: Good binding with balanced physicochemical properties\n\n### 5. Final Recommendations\n\nBased on our comprehensive optimization process, I recommend the following compounds as the most promising candidates for further development:\n\n1. **MC:I3:N2:G3** (pyridine-pyrazole with isoxazole): Excellent binding (-12.41 kcal/mol) with good drug-likeness (QED 0.48)\n2. **MC:I3:N3:G3** (pyridine-pyrazole with cyclopropylurea): Best drug-likeness (QED 0.60) with good binding (-10.83 kcal/mol)\n3. **MC:I3:N5:G3** (benzoquinazoline with oxazole): Highest binding affinity (-13.42 kcal/mol)\n4. **MC:I3:N8:G3** (piperidine with cyclopropylmethoxy): Good binding (-11.48 kcal/mol) with balanced properties\n\nThese compounds represent diverse chemical space and binding modes, providing multiple avenues for further optimization and development as AKT1 inhibitors.'}]
```

---

## User

```
[{'type': 'text', 'text': 'Ranking Agent, for iteration 3/3, rank the molecules discussed so far. Provide your top candidates and the ranking rationale. Follow the molecule sharing format.Always keep the format for the molecules of previous agent, DO NOT MODIFY ANY METRICS OR ID.Your role is just to rank the molecules, do not modify anything.'}]
```

---

## Assistant

```
[{'type': 'text', 'text': "# Ranking Agent Analysis for Iteration 3: Final Lead Optimization\n\nAs the Ranking Agent, I'll now analyze and rank all molecules discussed throughout our AKT1 inhibitor discovery project. My goal is to synthesize cross-domain insights from the data provided and produce a comprehensive ranking of the best candidate molecules.\n\n## Ranking Methodology\n\nFor this final iteration, I'll use a comprehensive evaluation framework that considers multiple parameters:\n\n1. **Docking Score** (35% weight): Primary indicator of binding affinity to AKT1\n2. **Drug-likeness (QED)** (25% weight): Measure of overall pharmaceutical quality\n3. **Lipophilicity (LogP)** (15% weight): Optimal range of 2-5 for oral bioavailability\n4. **Molecular Weight** (10% weight): Penalty for MW > 500 Da\n5. **Synthetic Accessibility (SA Score)** (10% weight): Lower is better\n6. **Protein-Ligand Interactions** (5% weight): Quality and quantity of key interactions\n\nI'll also consider specific interactions with AKT1-specific residues and potential metabolic liabilities.\n\n## Comprehensive Analysis of All Molecules\n\nAfter analyzing all molecules from iterations 1-3, I've identified several key trends:\n\n1. The pyridine-pyrazole scaffold (derived from AI:I1:N5:G0) consistently provides the best balance of binding affinity and drug-likeness\n2. The benzoquinazoline scaffold (derived from DA:I1:N5:G0) offers excellent binding but struggles with drug-likeness\n3. The piperidine-containing scaffold (derived from AI:I1:N1:G0) provides good binding with balanced physicochemical properties\n4. Iteration 3 modifications successfully addressed key concerns from previous iterations, particularly regarding metabolic stability and toxicity\n\n## Final Ranking of Top 10 AKT1 Inhibitor Candidates"}]
```

---

## Assistant

```
[{'type': 'text', 'text': '<molecules>\n{\n    "ranking": [\n        {\n            "rank": 1,\n            "friendly_id": "MC:I3:N2:G3",\n            "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)c1cc(C)no1",\n            "metrics": {\n                "docking": "-12.41",\n                "qed": "0.48",\n                "sa_score": "3.46",\n                "logp": "3.05",\n                "molecular_weight": "453.55"\n            },\n            "rationale": "This pyridine-pyrazole derivative achieves an exceptional balance of binding affinity and drug-likeness. With a docking score of -12.41 kcal/mol, it shows excellent binding to AKT1 while maintaining good drug-likeness (QED 0.48). The isoxazole bioisostere successfully replaces the potentially toxic fluoroacetamide while forming additional hydrogen bonds with key residues. Its optimal lipophilicity (logP 3.05) and reasonable molecular weight (453.55 Da) suggest good oral bioavailability. The compound forms critical interactions with TRP80 (pi-stacking) and multiple hydrogen bonds with ASN204, SER205, THR211, ASP274, ASP292, and GLY294."\n        },\n        {\n            "rank": 2,\n            "friendly_id": "MC:I3:N3:G3",\n            "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)N1CC1",\n            "metrics": {\n                "docking": "-10.83",\n                "qed": "0.60",\n                "sa_score": "3.32",\n                "logp": "2.35",\n                "molecular_weight": "413.53"\n            },\n            "rationale": "This compound offers the best drug-likeness (QED 0.60) among all candidates while maintaining excellent binding affinity (-10.83 kcal/mol). The cyclopropylurea replacement for the fluoroacetamide addresses toxicity concerns while providing metabolic stability. With the lowest molecular weight (413.53 Da) among the top candidates and optimal lipophilicity (logP 2.35), this compound has excellent potential for oral bioavailability. It forms key hydrogen bonds with ASN204, SER205, HIS207, and THR211, and maintains pi-stacking with TRP80."\n        },\n        {\n            "rank": 3,\n            "friendly_id": "MC:I3:N1:G3",\n            "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)c1cc(C)on1",\n            "metrics": {\n                "docking": "-11.79",\n                "qed": "0.48",\n                "sa_score": "3.42",\n                "logp": "3.05",\n                "molecular_weight": "453.55"\n            },\n            "rationale": "This pyridine-pyrazole derivative shows excellent binding affinity (-11.79 kcal/mol) with good drug-likeness (QED 0.48). The methylisoxazole-carboxamide bioisostere successfully addresses the toxicity concerns of the fluoroacetamide while maintaining key interactions. The compound has optimal lipophilicity (logP 3.05) and reasonable molecular weight (453.55 Da). It forms multiple hydrogen bonds with key residues (ASN204, SER205, THR211, TYR272, THR82) and maintains pi-stacking with TRP80."\n        },\n        {\n            "rank": 4,\n            "friendly_id": "MC:I3:N8:G3",\n            "smiles": "CC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(OC4CC4)C5=C3CCC5F)CC2)C(=O)NC1C6=C(F)C=CC=C6F",\n            "metrics": {\n                "docking": "-11.48",\n                "qed": "0.39",\n                "sa_score": "4.60",\n                "logp": "3.60",\n                "molecular_weight": "586.66"\n            },\n            "rationale": "This optimized piperidine-containing scaffold shows excellent binding affinity (-11.48 kcal/mol) with acceptable drug-likeness (QED 0.39). The introduction of a cyclopropylmethoxy group and fluorine substituents enhances metabolic stability while maintaining key interactions. The compound has optimal lipophilicity (logP 3.60) though its molecular weight (586.66 Da) is somewhat high. It forms a key hydrogen bond with SER205 and a halogen bond with ARG273, enhancing binding stability."\n        },\n        {\n            "rank": 5,\n            "friendly_id": "MC:I3:N4:G3",\n            "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC(F)F)C3)=C1CCNC(=O)C1CC1",\n            "metrics": {\n                "docking": "-10.52",\n                "qed": "0.54",\n                "sa_score": "3.49",\n                "logp": "3.44",\n                "molecular_weight": "448.52"\n            },\n            "rationale": "This pyridine-pyrazole derivative offers a good balance of binding affinity (-10.52 kcal/mol) and drug-likeness (QED 0.54). The difluoromethoxy group enhances metabolic stability and forms a halogen bond with THR211, while the cyclopropylcarboxamide provides a stable replacement for the carbamate. The compound has optimal lipophilicity (logP 3.44) and reasonable molecular weight (448.52 Da). It forms hydrogen bonds with SER205, HIS207, and THR211, and maintains pi-stacking with TRP80."\n        },\n        {\n            "rank": 6,\n            "friendly_id": "MC:I3:N10:G3",\n            "smiles": "CC(OC)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5F",\n            "metrics": {\n                "docking": "-10.46",\n                "qed": "0.44",\n                "sa_score": "4.25",\n                "logp": "2.95",\n                "molecular_weight": "542.63"\n            },\n            "rationale": "This optimized piperidine-containing scaffold shows good binding affinity (-10.46 kcal/mol) with acceptable drug-likeness (QED 0.44). The methoxy protection of the hydroxyl group enhances metabolic stability, while the consistent difluoro substitution pattern improves predictability of metabolism. The compound has optimal lipophilicity (logP 2.95) though its molecular weight (542.63 Da) is somewhat high. It forms multiple hydrogen bonds with key residues and a halogen bond with TYR272."\n        },\n        {\n            "rank": 7,\n            "friendly_id": "MC:I3:N9:G3",\n            "smiles": "CC(O)NCC(N1C(=O)CN2CCC(C3=CC=C(O)C4=C3CCC4)CC2)C(=O)NC1C5=C(F)C=CC=C5F",\n            "metrics": {\n                "docking": "-10.15",\n                "qed": "0.41",\n                "sa_score": "4.17",\n                "logp": "2.29",\n                "molecular_weight": "528.60"\n            },\n            "rationale": "This optimized piperidine-containing scaffold shows good binding affinity (-10.15 kcal/mol) with acceptable drug-likeness (QED 0.41). The consistent difluoro substitution pattern improves metabolic stability compared to the mixed halogen pattern in the parent compound. The compound has excellent lipophilicity (logP 2.29) for optimal solubility, though its molecular weight (528.60 Da) is somewhat high. It forms multiple hydrogen bonds with key residues including GLN203, SER205, THR211, THR291, and ASN53."\n        },\n        {\n            "rank": 8,\n            "friendly_id": "MC:I2:N5:G2",\n            "smiles": "CC1=NC(NC=2C=C(C)[NH1]N=2)=CC(N3CCCC(OC)C3)=C1CCNC(=O)CF",\n            "metrics": {\n                "docking": "-10.59",\n                "qed": "0.63",\n                "sa_score": "3.45",\n                "logp": "2.41",\n                "molecular_weight": "404.49"\n            },\n            "rationale": "This pyridine-pyrazole derivative from Iteration 2 still ranks highly due to its excellent drug-likeness (QED 0.63, the highest among all candidates) and good binding affinity (-10.59 kcal/mol). While the fluoroacetamide group presents potential toxicity concerns (addressed in Iteration 3 derivatives), the compound has optimal lipophilicity (logP 2.41) and low molecular weight (404.49 Da). It forms critical interactions with TRP80 (pi-stacking) and multiple hydrogen bonds with key residues."\n        },\n        {\n            "rank": 9,\n            "friendly_id": "MC:I3:N5:G3",\n            "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(O)cc4nc3-c3coc(N4CCOCC4)n3)cc2)CC1",\n            "metrics": {\n                "docking": "-13.42",\n                "qed": "0.26",\n                "sa_score": "3.17",\n                "logp": "5.39",\n                "molecular_weight": "603.68"\n            },\n            "rationale": "This benzoquinazoline derivative shows the highest binding affinity (-13.42 kcal/mol) among all candidates, but ranks lower due to suboptimal drug-likeness (QED 0.26), high lipophilicity (logP 5.39), and high molecular weight (603.68 Da). Nevertheless, it forms an impressive array of interactions, including hydrogen bonds with GLN203, SER205, LYS268, ASP274, ASN279, PHE293, and THR82, as well as pi-stacking with TRP80 and pi-cation interaction with LYS179."\n        },\n        {\n            "rank": 10,\n            "friendly_id": "MC:I3:N6:G3",\n            "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3ncc(O)cc3-c3cnn(CCN4CCOCC4)c3)cc2)CC1",\n            "metrics": {\n                "docking": "-12.53",\n                "qed": "0.28",\n                "sa_score": "3.00",\n                "logp": "4.54",\n                "molecular_weight": "579.71"\n            },\n            "rationale": "This modified benzoquinazoline derivative shows excellent binding affinity (-12.53 kcal/mol) with improved lipophilicity (logP 4.54) compared to other benzoquinazoline derivatives. While its drug-likeness (QED 0.28) and molecular weight (579.71 Da) are suboptimal, it has good synthetic accessibility (SA score 3.00) and forms key hydrogen bonds with ASN204, SER205, ALA58, and GLN79, as well as pi-stacking with TRP80."\n        }\n    ],\n    "summary": "The final ranking prioritizes compounds with balanced profiles of binding affinity, drug-likeness, and physicochemical properties. The pyridine-pyrazole scaffold dominates the top positions (ranks 1-3, 5, 8) due to its exceptional balance of potency and drug-likeness, with MC:I3:N2:G3 emerging as the top candidate. The piperidine-containing scaffold provides good candidates with balanced properties (ranks 4, 6, 7), while the benzoquinazoline scaffold, despite showing the highest binding affinities, ranks lower (positions 9-10) due to suboptimal drug-likeness and physicochemical properties. All top-ranked compounds successfully address the key concerns identified in previous iterations, particularly regarding metabolic stability and potential toxicity. The top 10 compounds represent diverse chemical space and binding modes, providing multiple avenues for further development as AKT1 inhibitors."\n}\n</molecules>\n\n## Detailed Ranking Analysis\n\n### Top-Tier Compounds (Ranks 1-3)\n\nThe top three positions are dominated by the pyridine-pyrazole scaffold, which consistently provides the best balance of binding affinity and drug-likeness:\n\n1. **MC:I3:N2:G3** (Rank 1): This compound achieves an exceptional balance with excellent binding (-12.41 kcal/mol) and good drug-likeness (QED 0.48). The isoxazole bioisostere successfully addresses toxicity concerns while forming additional hydrogen bonds with key residues.\n\n2. **MC:I3:N3:G3** (Rank 2): This compound offers the best drug-likeness (QED 0.60) among all candidates while maintaining excellent binding (-10.83 kcal/mol). Its cyclopropylurea replacement provides metabolic stability with the lowest molecular weight (413.53 Da) among top candidates.\n\n3. **MC:I3:N1:G3** (Rank 3): Similar to the top-ranked compound but with the isoxazole in a different orientation, this molecule shows excellent binding (-11.79 kcal/mol) with good drug-likeness (QED 0.48).\n\n### Mid-Tier Compounds (Ranks 4-7)\n\nThe middle tier includes a mix of piperidine-containing and pyridine-pyrazole scaffolds:\n\n4. **MC:I3:N8:G3** (Rank 4): The highest-ranked piperidine-containing scaffold with excellent binding (-11.48 kcal/mol) and metabolic stability enhancements.\n\n5. **MC:I3:N4:G3** (Rank 5): A pyridine-pyrazole derivative with good balance of binding (-10.52 kcal/mol) and drug-likeness (QED 0.54).\n\n6-7. **MC:I3:N10:G3 & MC:I3:N9:G3** (Ranks 6-7): Optimized piperidine-containing scaffolds with good binding and acceptable drug-likeness.\n\n### Lower-Tier Compounds (Ranks 8-10)\n\nThe lower tier includes a previous iteration compound and benzoquinazoline derivatives:\n\n8. **MC:I2:N5:G2** (Rank 8): This Iteration 2 compound still ranks well due to its excellent drug-likeness (QED 0.63) despite toxicity concerns.\n\n9-10. **MC:I3:N5:G3 & MC:I3:N6:G3** (Ranks 9-10): Benzoquinazoline derivatives with the highest binding affinities (-13.42 and -12.53 kcal/mol) but suboptimal drug-likeness and physicochemical properties.\n\n## Scaffold Distribution in Final Ranking\n\n- **Pyridine-Pyrazole Scaffold**: 5 compounds (ranks 1, 2, 3, 5, 8)\n- **Piperidine-Containing Scaffold**: 3 compounds (ranks 4, 6, 7)\n- **Benzoquinazoline Scaffold**: 2 compounds (ranks 9, 10)\n\n## Key Structure-Activity Relationship (SAR) Insights\n\n1. **Binding Affinity Determinants**:\n   - Pi-stacking with TRP80 is essential across all scaffolds\n   - Multiple hydrogen bonds with SER205, THR211, and ASP292 enhance binding\n   - Halogen bonds can provide additional binding stability\n\n2. **Drug-Likeness Factors**:\n   - Molecular weight below 450 Da correlates with better QED scores\n   - LogP between 2-3.5 provides optimal balance of solubility and permeability\n   - Cyclic amides and ureas offer better drug-likeness than linear analogs\n\n3. **Metabolic Stability Enhancements**:\n   - Isoxazole and cyclopropyl groups serve as metabolically stable bioisosteres\n   - Consistent halogenation patterns improve predictability of metabolism\n   - Methoxy protection of hydroxyl groups blocks metabolism at vulnerable sites\n\n## Conclusion\n\nThe final ranking represents a comprehensive evaluation of all molecules generated throughout our AKT1 inhibitor discovery project. The top-ranked compounds successfully address the key concerns identified in previous iterations, particularly regarding metabolic stability and potential toxicity, while maintaining or improving binding affinity.\n\nThe pyridine-pyrazole scaffold emerges as our most promising series, offering an exceptional balance of potency and drug-likeness. The top-ranked compound, MC:I3:N2:G3, represents the culmination of our optimization efforts, achieving excellent binding affinity (-12.41 kcal/mol) with good drug-likeness (QED 0.48) and optimal physicochemical properties.'}]
```

